Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by Wino115on Oct 13, 2022 9:19am
204 Views
Post# 35021874

Expectations too high. Reset your animus.

Expectations too high. Reset your animus.What was to be expected, frankly. They alway said they'd talk efficacy when it was scientifically proven with two or more patients.  We can assume, that is still the case.  

My hopes were for more quantitative facts on enrollment, survival, etc... We didn't get that. But we did get a rough estimate. We are 5 months in and they said the are on "pace" for full enrollment at worse in 5 more months.  The implication is that they are likely around 50% at this point. I would guess part of the issue is what we already know --these patients are at the very end of life and need to survive long enough for any therapy to work throught.  

But my guess is they are probably dosing around 25 or so patients at this point. 
<< Previous
Bullboard Posts
Next >>